Terlipressin, marketed under the brand name Terlivaz, was approved by the FDA on September 14, 2022.

Jul 24th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Deucravacitinib, marketed under the brand name Sotyktu, was approved by the FDA on September 9, 2022.

Nuvalent reported the launch of HEROEX-1, its Phase 1a/1b clinical study testing the new HER2-selective inhibitor NVL-330.

Daxxify, with the generic name daxibotulinumtoxinA-lanm, is an FDA-approved medication used for both cosmetic and therapeutic purposes.

Johnson & Johnson is requesting U.S. FDA approval for SPRAVATO® (esketamine) as the sole treatment for adults with treatment-resistant depression.

Spesolimab, marketed under the brand name Spevigo, received FDA approval for the treatment of generalized pustular psoriasis flares in adults.

This study assessed the safety, tolerability, and pharmacokinetics of their leading lipidated IL-22 candidate, CK-0045.

Auvelity, under its generic name bupropion and dextromethorphan, has been approved by the FDA for the treatment of major depressive disorder.

The European Medicines Agency has approved Bristol Myers Squibb's application to use Opdivo (nivolumab) and Yervoy (ipilimumab) as initial treatments.

Venlafaxine received FDA approval for the treatment of major depressive disorder on December 28, 1993.

NGM Bio Secures $122 Million in Series A to Launch Primary Sclerosing Cholangitis Trial and Support Phase 2 Hyperemesis Gravidarum Study.